Fletcher JW et al. - In a trial to develop recommendations on use of 18F-FDG PET in breast, colorectal, esophageal, head and neck, lung, pancreatic, and thyroid cancer; lymphoma, melanoma, and sarcoma; and unknown primary tumor, it was recommended that 18F-FDG PET should be used as an imaging tool in addition to conventional radiologic methods such as CT or MRI Methods
A search was performed to identify all published randomized controlled trials and systematic reviews in the literature
An additional search was performed to identify relevant unpublished systematic reviews
Publications comprised both retrospective and prospective studies of varied methodologic quality
Anticipated consequences of false-positive and false-negative tests when evaluating clinical usefulness, and impact of 18F-FDG PET on management of cancer pts, were also reviewed
Results
18F-FDG PET should be used as an imaging tool in addition to conventional radiologic methods such as CT or MRI
Any positive finding that could lead to a clinically significant change in pt management should be confirmed by subsequent histopathologic examination because of the risk of false-positive results
18F-FDG PET should be used in the appropriate clinical setting for the diagnosis of head and neck, lung, or pancreatic cancer and for unknown primary tumor
See all
